Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Hospital Labs Look to Reduce MDx Send-Outs
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' on Cepheid (NASDAQ: CPHD), PT $27.
Canaccord analyst says, "We reiterate our rating on CPHD ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "We reiterate our rating on CPHD ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
